Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Hyperglycemia 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma 2Leukemia 2Leukemia, Myeloid, Acute 1Diabetes Mellitus, Type 2 1Congenital Abnormalities 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 217Rituximab 110Etoposide 99Peripheral Blood Stem Cell Transplantation 94Vincristine 91Filgrastim 91Cytarabine 91Methotrexate 90fludarabine phosphate 85Radiotherapy 67Doxorubicin 67Prednisone 66Dexamethasone 57Mycophenolic Acid 53Cyclosporine 53Whole-Body Irradiation 50Busulfan 47Melphalan 44blinatumomab 43Tacrolimus 42fludarabine 41Antilymphocyte Serum 40Methylprednisolone 39merphos 35Calcium Dobesilate 34Leucovorin 33Granulocyte Colony-Stimulating Factor 30Mercaptopurine 26dexamethasone acetate 25dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Burkitt Lymphoma × Insulin Glargine × Lymphoid × Clear all
NCT00500240 2015-06-03

Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)

M.D. Anderson Cancer Center

Phase 3 Terminated
52 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hyperglycemia, Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡